MA-AMYLYX
26.10.2021 14:52:05 CEST | Business Wire | Press release
Amylyx Pharmaceuticals, Inc. today announced the appointment of Stéphanie Hoffmann-Gendebien, MBA, as Head, General Manager in Europe, the Middle East and Africa (EMEA). Ms. Hoffmann-Gendebien brings more than 20 years of leadership experience in the pharmaceutical and biotechnology industries with deep expertise in orphan drug development and commercialization. The first European entity of Amylyx, Amylyx Pharmaceuticals EMEA B.V., is incorporated in the Netherlands and is establishing a presence and team in Europe in order to be closer to the patient community, centers of excellence in medicine and regulatory authorities in regions for which Ms. Hoffmann-Gendebien will manage and oversee at Amylyx. Amylyx will establish its EMEA headquarters in the Zuidas district, Amsterdam, and plans a future expansion into the Middle East and Africa markets.
“At Amylyx, we are determined to help people living with ALS around the world. By expanding our organization in Europe, we can build deeper relationships with local ALS communities and understand their unique needs. With Stéphanie’s extensive global commercial and rare disease experience, and talent for developing long lasting partnerships with advocacy groups, researchers and clinicians, we are confident in her ability to lead Amylyx’ European organization,” said Margaret Olinger, Chief Commercial Officer at Amylyx. “Alongside an already impressive track record, we are certain with Stéphanie’s hands-on leadership style and can-do attitude, she will help us build an incredible team and significant presence across the continent. We’re truly honored to have her join the Amylyx team.”
In her career, Ms. Hoffmann-Gendebien has successfully led the launch of two orphan drugs in Europe and directed global market development, global patient advocacy, European market access and European launch planning for two additional orphan drugs. Most recently, Ms. Hoffmann-Gendebien served as managing director and founding partner of GH PARTNERS, a management consulting company providing consulting services for biotechnology companies involved in rare diseases and orphan drug development. GH PARTNERS provided guidance and consulting to companies related to market development, market access, patient advocacy, general management, orphan drug launch planning and commercialization.
“I was inspired by what I learned about the dedication and urgency with which the entire Amylyx team works to effectively advance AMX0035 through the clinical and commercial development process to help the global ALS community,” said Ms. Hoffmann-Gendebien. “Their willingness to listen and learn from advocacy groups to understand the unique needs of people with ALS is astonishing and makes me proud to join the company. Amylyx is at the forefront of advancing new treatments in neurodegenerative diseases and I am delighted to have the opportunity to develop this organization’s European presence and build out an agile team to serve this market.”
Prior to joining Amylyx, Ms. Hoffmann-Gendebien served as vice president, general manager, Europe, Middle East & Africa (EMEA) at Clementia Pharmaceuticals Inc. Prior to Clementia, she was the European director of strategic market development at Enobia Pharma (Alexion Pharmaceuticals, Inc.) and held roles of increasing responsibility in the therapeutics division Genzyme Europe BV (now Sanofi Genzyme). She serves on the board of directors at Secoya Technologies, a role she has held since April 2020, and volunteers with the European Organisation for Rare Diseases (EURORDIS), a non-governmental patient-driven alliance of rare disease patient organizations. Ms. Hoffmann-Gendebien received a bachelor’s degree in chemistry and an MBA from the Université catholique de Louvain in Louvain-la-Neuve, Belgium.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005775/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 10:52:00 CEST | Press release
IRIS² expands SES's differentiated MEO architecture while supporting Europe's secure, sovereign multi-orbit connectivity ambitions SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously commun
Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 07:10:00 CEST | Press release
2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SETotal business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment effec
Pure Lithium Receives Australian Patent for "Lithium Metal Anode and Battery"6.8.2026 22:49:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated next-generation lithium metal battery technology company, today announced that the Australian patent office has granted the company a patent (AU2025271196) titled “Lithium metal anode and battery.” Australia mines roughly half of the world’s lithium, yet has no domestic battery production at all; every battery the country uses is imported. The granted patent is directed to ways in which Pure Lithium’s technology can change that. Rather than trying to catch up in lithium-ion, Australia can leapfrog the incumbent technology and establish a next-generation industry. As worldwide demand for batteries grows, every country capable of making batteries needs to be making them. That is Pure Lithium’s central goal: opening up markets around the world through battery technology that enables local, independent supply chains, keeping pace with demand and strengthening economies. China controls the lithium-ion battery supply chain and manufactures th
Vercel Appoints Amit Agarwal, Standard Template Labs CEO and former Datadog President, to Board of Directors6.8.2026 17:00:00 CEST | Press release
The product leader who helped scale Datadog from early-stage startup through IPO brings deep product expertise to Vercel's board Vercel, the agentic infrastructure company, today announced the appointment of Amit Agarwal, former president of Datadog and founder and CEO of Standard Template Labs, an AI-first service management platform, to its board of directors. Agarwal brings 25 years of enterprise software experience and a track record of scaling a product-led company from its earliest days into one of the defining public software companies of the cloud era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806738617/en/ Amit Agarwal Agarwal joined Datadog in 2012 as its Chief Product Officer and was named President in 2022, overseeing product, corporate development, and go-to-market functions as the company grew past $2.5 billion in annual revenue. Across 13 years, including Datadog's 2019 IPO and its first years as a pub
Laserfiche Launches Advanced Enterprise Security to Deliver Multi-Region Disaster Recovery and GovRAMP-Ready Compliance for Highly Regulated Industries6.8.2026 16:00:00 CEST | Press release
New security suite extends Laserfiche’s proven security controls and adds near real-time data replication for governments, law enforcement and security-conscious enterprises. Laserfiche — the leading SaaS provider of intelligent content management — today announced the launch of Enterprise Security, an advanced suite of security enhancements designed for organizations navigating complex regulatory environments. Enterprise Security addresses GovRAMP and CJIS (Criminal Justice Information Services) security requirements based on the NIST SP 800-53 framework. For organizations handling privileged citizen, legal or corporate data, these built-in controls streamline audit preparation and fortify defenses. With organizations placing a higher priority on data stewardship and corporate governance, enterprise IT leaders require a security architecture that protects data without slowing down operations. Laserfiche Enterprise Security extends Laserfiche Cloud’s highly resilient infrastructure wit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom